Literature DB >> 14659561

A 25 kDa cleavage product of polypyrimidine tract binding protein (PTB) present in mouse tissues prevents PTB binding to the 5' untranslated region and inhibits translation of hepatitis A virus RNA.

Musturi Venkatramana1, Partho Sarothi Ray, Ankita Chadda, Saumitra Das.   

Abstract

The 5' untranslated region (5'UTR) of the hepatitis A virus (HAV) genomic RNA contains an internal ribosome entry site (IRES) which interacts with various cellular proteins and facilitates cap-independent translation. We report the interaction of a 25kDa protein (p25), present in certain murine tissues and most abundantly in mouse kidney, with the HAV 5'UTR. This protein was found to be a cleavage product of the polypyrimidine tract-binding protein (PTB) and competed with it for binding to the HAV 5'UTR RNA. The binding site of p25 overlapped with the reported binding site of PTB. Exogenous addition of partially purified p25 to in vitro translation reactions resulted in the inhibition of HAV IRES-mediated translation, which could be rescued by the addition of purified PTB. These results suggest that p25 is a cleavage product of PTB which binds to the HAV IRES and antagonizes the translation-stimulating activity of PTB. The presence of the 25kDa cleavage product of PTB may therefore play a role in the inhibition of HAV IRES-mediated translation in mouse tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659561     DOI: 10.1016/j.virusres.2003.09.004

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  A polypyrimidine tract binding protein, pumpkin RBP50, forms the basis of a phloem-mobile ribonucleoprotein complex.

Authors:  Byung-Kook Ham; Jeri L Brandom; Beatriz Xoconostle-Cázares; Vanessa Ringgold; Tony J Lough; William J Lucas
Journal:  Plant Cell       Date:  2009-01-02       Impact factor: 11.277

2.  A peptide derived from RNA recognition motif 2 of human la protein binds to hepatitis C virus internal ribosome entry site, prevents ribosomal assembly, and inhibits internal initiation of translation.

Authors:  Renuka Pudi; Sudhamani S Ramamurthy; Saumitra Das
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Cellular Proteins Act as Bridge Between 5' and 3' Ends of the Coxsackievirus B3 Mediating Genome Circularization During RNA Translation.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Curr Microbiol       Date:  2015-07-03       Impact factor: 2.188

Review 4.  Picornaviruses and RNA Metabolism: Local and Global Effects of Infection.

Authors:  Autumn C Holmes; Bert L Semler
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 5.  Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Masato Nakamura; Xia Jiang; Yuki Haga; Reina Sasaki; Osamu Yokosuka
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

6.  Role of polypyrimidine tract binding protein in mediating internal initiation of translation of interferon regulatory factor 2 RNA.

Authors:  Debojyoti Dhar; Musturi Venkataramana; Anand Ponnuswamy; Saumitra Das
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

7.  Translational control of the interferon regulatory factor 2 mRNA by IRES element.

Authors:  Debojyoti Dhar; Swagata Roy; Saumitra Das
Journal:  Nucleic Acids Res       Date:  2007-08-13       Impact factor: 16.971

Review 8.  New insights into functional roles of the polypyrimidine tract-binding protein.

Authors:  Maria Grazia Romanelli; Erica Diani; Patricia Marie-Jeanne Lievens
Journal:  Int J Mol Sci       Date:  2013-11-20       Impact factor: 5.923

9.  Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Shingo Nakamoto; Kengo Saito; Hiroshi Shirasawa; Tomoko Kiyohara; Koji Ishii; Takaji Wakita; Hiroaki Okamoto; Osamu Yokosuka
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.